Clinical trial
Safety and Immunogenicity of Three Commercially Available Influenza Vaccines in…
NCT00311428 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00311428 |
|---|---|
| Title | Safety and Immunogenicity of Three Commercially Available Influenza Vaccines in Children Aged 6 to <36 Months |
| Official title | A Phase IV, Observer-Blind, Randomized, Parallel Groups, Single-Center, Exploratory Clinical Study to Evaluate the Immunogenicity and Safety of Two 0.25 mL Intramuscular Doses of Three Commercially Available Influenza Vaccines in Healthy Subjects Aged 6 to <36 Months. |
| Lead sponsor | Novartis, Industry |
| Collaborators | Novartis Vaccines Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Influenza |
| Intervention type | Biological |
| Interventions | Influenza |
| Enrollment | 270 |
| Start date | Oct 1, 2005 |
| First posted | Apr 6, 2006 |
| Last update posted | Sep 14, 2006 |
| Countries | Finland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: